News
RANI
0.8398
+4.27%
0.0344
Weekly Report: what happened at RANI last week (0330-0403)?
Weekly Report · 6h ago
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 4d ago
Rani Therapeutics Price Target Cut to $5.00/Share From $9.00 by Canaccord Genuity
Dow Jones · 4d ago
Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5
Benzinga · 4d ago
Analysts Conflicted on These Healthcare Names: Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (APLS)
TipRanks · 5d ago
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
TipRanks · 5d ago
Weekly Report: what happened at RANI last week (0323-0327)?
Weekly Report · 03/30 10:42
Rani Therapeutics files initial beneficial ownership statement; Chief Technical Officer Alireza Javadi reports 10,075 Class A shares
Reuters · 03/27 23:47
Rani Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 03/27 11:00
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
Benzinga · 03/27 10:50
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Mirum Pharmaceuticals (MIRM) and NovoCure (NVCR)
TipRanks · 03/27 10:20
Rani Therapeutics' net loss narrows in Q4 as costs fall
Reuters · 03/26 20:26
Rani Therapeutics GAAP EPS of -$0.07 in-line, revenue of $1.46M misses by $3.54M
Seeking Alpha · 03/26 20:23
Rani Therapeutics FY2025 net loss narrows 27.6% to $41 million; revenue rises 58.9% to $1.6 million
Reuters · 03/26 20:11
*Rani Therapeutics 4Q Loss/Shr 7c >RANI
Dow Jones · 03/26 20:11
*Rani Therapeutics Sees Funding Sufficient Into 4Q27 >RANI
Dow Jones · 03/26 20:11
*Rani Therapeutics 4Q Rev $1.5M >RANI
Dow Jones · 03/26 20:10
Rani Therapeutics Hldgs Q4 EPS $(0.07) Misses $(0.06) Estimate, Sales $1.461M Miss $5.000M Estimate
Benzinga · 03/26 20:06
RANI THERAPEUTICS Q4 OPERATING EXPENSES USD 9.995 MILLION
Reuters · 03/26 20:05
Press Release: Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
Dow Jones · 03/26 20:05
More
Webull provides a variety of real-time RANI stock news. You can receive the latest news about Rani Therapeutics Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).